Amaero (3DA) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
31 Mar, 2026Executive summary
Completed corporate restructuring and relocated headquarters and operations from Australia to Tennessee, USA, to become a leading U.S. supplier of C103, refractory, and titanium alloy powders for defense and space industries.
Ceased Australian operations to focus on U.S. market, leveraging significant economic incentives and a 15-year lease on a 100,000 sq ft facility.
Hired key executives with deep industry experience and appointed former U.S. National Security Advisor H.R. McMaster as Special Advisor.
Secured a binding offtake and preferred supplier agreement for C103 AM powder with ADDMAN Group, achieving qualification ahead of schedule.
Financial highlights
Reported net loss of A$18.8 million for FY2024, compared to A$12.5 million in FY2023.
Revenue from continuing operations was A$463,856, up from A$68,301 in FY2023.
Cash and cash equivalents at 30 June 2024 were A$12.0 million.
Completed two equity capital raises totaling A$30 million during FY2024, plus an additional A$25 million post year-end.
Outlook and guidance
Targeting EBITDA breakeven in FY2026, underpinned by material revenue from C103 offtake agreements.
Expect to commence commercial sales in Q3 FY2025 and commission a second atomizer by June 2025.
Ti-64 powder qualification expected by end of CY2024.
Latest events from Amaero
- Stockholders voted on equity plans, share issuance, and director compensation changes.3DA
EGM 2026 - Revenue up 376% to $18.1M, but net loss widened; strong backlog amid going concern risk.3DA
H2 2026 - Record revenue growth, strong backlog, and U.S. IPO plans mark a pivotal year.3DA
Q4 2026 TU - Poised for rapid growth, Amaero leads U.S. advanced powder production and targets a U.S. IPO.3DA
IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 - Shareholders and option holders strongly approved all proposed schemes and director option grants.3DA
Scheme Meeting 2026 presentation - Q3 FY2026 revenue up 301%–347% YoY, FY2026 fully contracted, U.S. redomiciliation advances.3DA
Q3 2026 TU - FY2025 saw record revenue, major supply deals, and facility expansion, setting up strong FY2026 growth.3DA
H2 2025 - Revenue up 367%, net loss widens, FY2026 guidance cut amid U.S. contract delays.3DA
H1 2026 - Transition to commercialization, capital raises, and U.S. expansion with new leadership.3DA
AGM 2024